| Literature DB >> 31181104 |
Cléa Melenotte1, Soraya Mezouar1, Amira Ben Amara1, Simon Benatti2, Jacques Chiaroni3,4, Christian Devaux1, Régis Costello5, Guido Kroemer6,7,8,9,10,11,12,13, Jean-Louis Mege1, Didier Raoult1.
Abstract
Coxiella burnetii, the agent causing Q fever, has been associated with B-cell non-Hodgkin lymphoma (NHL). To better clarify this link, we analysed the genetic transcriptomic profile of peripheral blood leukocytes from patients with C. burnetii infection to identify possible links to lymphoma. Microarray analyses revealed that 1189 genes were expressed differently (p <.001 and fold change ≥4) in whole blood of patients with C. burnetii infection compared to controls. In addition, 95 genes expressed in patients with non-Hodgkin lymphoma (NHL) and in patients with C. burnetii persistent infection have allowed us to establish the 'C. burnetii-associated NHL signature'. Among these, 33 genes previously found modulated in C. burnetii-associated -NHL by the microarray analysis were selected and their mRNA expression levels were measured in distinct C. burnetii-induced pathologies, namely, acute Q fever, focalized persistent infection, lymphadenitis and C.burnetii-associated NHL. Specific genes involved in anti-apoptotic process were found highly expressed in leukocytes from patients with C. burnetii associated-NHL: MIR17HG, REL and SP100. This signature differed from that found for NHL-control group. Patients with C. burnetii lymphadenitis presented significant elevated levels of BCL2 and ETS1 mRNAs. Altogether, we identified a specific transcriptionnal signature for NHL during C. burnetii infection reflecting the up-regulation of anti-apoptotic processes and the fact that lymphadenitis might constitute a critical step towards lymphomagenesis.Entities:
Mesh:
Year: 2019 PMID: 31181104 PMCID: PMC6557487 DOI: 10.1371/journal.pone.0217542
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patients with C. burnetii infection characteristic for microarray analysis.
| Patients characteristics | Acute Q fever | |
|---|---|---|
| N = | 8 | 8 |
| Sex (men/women) | 6/2 | 6/2 |
| Age (mean±SD) | 45±15 | 56±24 |
| Endocarditis | 0 | 6 |
| Vascular infection | 0 | 1 |
| Hepatitis | 5 | 1 |
| Pneumonia | 2 | 0 |
| Flu-like syndrome | 1 | 0 |
| IgG I mediane [IQR] | 75 [12.5–300] | 6400 [25600–24800] |
| IgG II mediane [IQR] | 800 [400–2000] | 18 000 [6400–19200] |
| IgM II mediane [IQR] | 300 [150–1200] | 25 [0–425] |
| Doxycycline alone | 8 | - |
| Doxycycline-Hydroxychloroquine | - | 8 |
| Surgery | 0 | 2 |
| Remission | 8 | 8 |
IQR: interquartile range
Patients characteristics for qRT-PCR analysis.
| Patients characteristics | Acute Q fever | ||||
|---|---|---|---|---|---|
| N = | 11 | 11 | 4 | 4 | 10 |
| Sex (men/women) | 7/4 | 8/3 | 4/0 | 2/2 | 3/7 |
| Age (mean±SD) | 43±16 | 58±13 | 56±16 | 73±11 | 63±18 |
| No | |||||
| Endocarditis | 0 | 10 | 1 | 2 | |
| Vascular infection | 0 | 1 | - | 1 | |
| Hepatitis | 9 | - | 1 | - | |
| Pneumonia | 1 | - | 1 | 1 | |
| Flu-like syndrome | 1 | - | - | - | |
| IgG I mediane [IQR] | 100 [0–200] | 1600 [800–12800] | 3400 [250–9600] | 500 [150–800] | Negative |
| IgG II mediane [IQR] | 1600 [800–2400] | 3200 [1600–9400] | 850 [1600–4200] | 1000 [400–1600] | |
| IgM II mediane [IQR] | 400 [100–800] | 0 [0–100] | 50 [0–100] | 0 [0–100] | |
| NA | |||||
| Doxycycline alone | 11 | - | - | - | |
| Doxycycline-Hydroxychloroquine | - | 11 | 4 | 1 | |
| Surgery | 0 | 0 | - | - | |
| Remission | 11 | 11 | 4 | 2 |
IQR: interquartile range, NA: not applicable
Fig 1Transcritpional profile of patients with C. burnetii infection.
Microarray transcriptional profile using whole blood from patients with C. burnetii infection and healthy donors. Differential gene expression contrasting patients with Q fever and healthy controls was analysed by (A) hierarchical clustering with samples in row and genes in column. Gene expression was colored from green (down-regulated) to red (up-regulated). (B) Graphic representation of the principal component analysis indicating patients with Q fever (in blue) and controls (in red). (C) Differentially expressed genes in Q fever patients were subjected to gene ontology (GO) annotation for biological processes. The percentages of GO terms are classified by groups of diseases and concern all patients with Q fever.
Fig 2Transcriptional profile of patients with C. burneti persistent infection links to lymphoma.
Microarray analyses were performed on whole blood from patients with persistent C. burnetii infection and healthy controls. Transcriptional profiles of patients with persistent C. burnetii infection were analyzed by (A) hierarchical clustering, (B) principal component analysis, (C) using IPA software to identify associated networks, and (D) according to the “disease or function” ontology of this software. (E) Comparison of the transcripitional effects of C. burnetii and S. aureus on genes linked to NHL or other cancers. The numbers at the top of each column indicates the number of genes incriminated.
C. burnetii—Non-Hodgkin lymphoma signature.
| Gene | Fold change | Gene description |
|---|---|---|
| ADAMTSL3 | 5.880324 | ADAMTS like 3 |
| AIF1 | -2.9805992 | Allograft inflammatory factor 1 |
| ALOX5 | -2.834 | Arachidonate 5-lipoxygenase |
| ANKIB1 | 4.8102517 | Ankyrin repeat and IBR domain containing 1 |
| ANKRD36 | 2.2068887 | Ankyrin repeat domain 36 |
| ASAP2 | -4.2549253 | ArfGAP with SH3 domain |
| ATP10A | -4.458795 | ATPase phospholipid transporting 10A (putative) |
| B2M | -3.521 | Beta-2-microglobulin |
| BAG1 | -2.899064 | BCL2 associated athanogene 1 |
| BCL2L11 | 2.6857266 | BCL2 like 11 |
| CASP10 | -1.7338927 | Caspase 10 |
| CASP2 | 3.9026406 | Caspase 2 |
| CASP4 | -2.6195037 | Caspase 4 |
| CASP8 | 3.4592438 | Caspase 8 |
| CCDC97 | -2.008394 | Coiled-coil domain containing 97 |
| CD44 | -2.1155155 | CD44 molecule |
| CD63 | -2.6959426 | CD63 molecule |
| CEBPB | -1.9058212 | CCAAT/enhancer binding protein beta |
| CNTRL | 2.5811584 | Centriolin |
| CREBBP | 3.0448112 | CREB binding protein |
| CTAGE1 | 3.4368377 | Cutaneous T-cell lymphoma-associated antigen 1 |
| CTAGE5 | 3.5890672 | CTAGE family member 5, export factor |
| CTNNB1 | 4.6916003 | Catenin beta 1 |
| CUL9 | -2.9435835 | Cullin 9 |
| DCLRE1C | 1.8426613 | DNA cross-link repair 1C |
| DNMT3B | -3.6707778 | DNA methyltransferase 3 beta |
| DYNLL2 | -2.3400176 | Dynein light chain LC8-type 2 |
| EGR1 | -3.795406 | Early growth response 1 |
| FBXO11 | 2.1503875 | F-box protein 11 |
| FYN | 3.284 | FYN proto-oncogene, src family tyrosine kinase |
| G6PD | 4.5535316 | Glucose-6-phosphate dehydrogenase |
| GNB1 | 1.9694024 | G protein subunit beta 1 |
| GP1BA | -3.7912498 | Glycoprotein Ib platelet alpha subunit |
| GRK3 | 3.358 | G protein-coupled receptor kinase 3 |
| HIC1 | 3.1705003 | Hypermethylated in cancer 1 |
| HLA-G | 5.7384872 | Major histocompatibility complex, class I, G |
| HUWE1 | 2.3448784 | HECT, UBA and WWE domain containing 1 |
| IKZF1 | 2.0111005 | IKAROS family zinc finger 1 |
| IL13RA1 | -2.7759755 | Interleukin 13 receptor subunit alpha 1 |
| IL2RG | 3.2423832 | Interleukin 2 receptor subunit gamma |
| ITGAX | -2.8220086 | Integrin subunit alpha X |
| JAK3 | -3.003575 | Janus kinase 3 |
| KIAA1551 | 3.162272 | KIAA1551 |
| KLHDC3 | 2.2549937 | Kelch domain containing 3 |
| KLHL6 | -3.3247852 | Kelch like family member 6 |
| KMT2C | 2.083985 | Lysine methyltransferase 2C |
| LIG3 | -2.9250553 | DNA ligase 3 |
| MAP3K8 | 2.3423563 | Mitogen-activated protein kinase kinase kinase 8 |
| MAP4K4 | 1.5909171 | Mitogen-activated protein kinase 4 |
| MED1 | -4.125631 | Mediator complex subunit 1 |
| MICALCL | -2.5829322 | MICAL C-terminal like |
| MIR17HG | 3.2123563 | miR-17-92a-1 cluster host gene |
| MKNK2 | -2.5849397 | MAP kinase interacting serine/threonine kinase 2 |
| NF1 | 2.524433 | Neurofibromin 1 |
| NFKBIA | -2.8016303 | Nuclear factor of Kappa light polypeptide gene enhancer in B cells inhibitor alpha |
| NIPBL | 3.1714787 | NIPBL, cohesin loading factor |
| NOTCH2 | -2.1726353 | Notch 2 |
| OGG1 | 2.5774076 | 8-oxoguanine DNA glycosylase |
| PBX1 | -3.845063 | PBX homeobox 1 |
| PLCG1 | 1.9097688 | Phospholipase C gamma 1 |
| PLEKHG3 | 2.318101 | Pleckstrin homology and RhoGEF domain containing G3 |
| PPP6R3 | 3.2296784 | Protein phosphatase 6 regulatory subunit 3 |
| PTPN11 | -3.1850703 | Protein tyrosine phosphatase, non-receptor type 11 |
| QARS | 3.6468294 | Glutaminyl-tRNA synthetase |
| RAPGEF1 | 3.936472 | Rap guanine nucleotide exchange factor 1 |
| RARA | -2.5248845 | Retinoic acid receptor alpha |
| REL | 1.7198911 | REL proto-oncogene, NF-kB subunit |
| RELB | -2.859732 | RELB proto-oncogene, NF-kB subunit |
| RPS2 | -3.7340784 | Ribosomal protein S2 |
| RPSA | -3.64 | Ribosomal protein SA |
| SERPINA1 | -2.598 | Serpin family A member 1 |
| SLC16A7 | 2.801318 | Solute carrier family 16 member 7 |
| SMARCA4 | 4.9222918 | SWI/SNF related actin dependent regulator of chromatin, subfamily a, member 4 |
| SMARCB1 | 3.59208 | SWI/SNF related actin dependent regulator of chromatin, subfamily b, member 1 |
| SP100 | 2.505 | SP100 nuclear antigen |
| SPECC1 | -2.0302236 | Sperm antigen with calponin homology and coiled-coil domains 1 |
| TDRD1 | 3.4261622 | Tudor domain containing 1 |
| TET2 | 5.2559843 | Tet methylcytosine dioxygenase 2 |
| TGFB1 | 2.3384285 | Transforming growth factor beta 1 |
| TLR7 | 4.3670783 | Toll like receptor 7 |
| TNFRSF8 | -1.8059382 | TNF receptor superfamily member 8 |
| TNIK | -2.174313 | TRAF2 and NCK interacting kinase |
| TPM1 | -4.584908 | Tropomyosin 1 (alpha) |
| TRAF1 | 1.6773132 | TNF receptor associated factor 1 |
| TRIM38 | 2.384246 | Tripartite motif containing 38 |
| TRIP12 | 2.4232147 | Thyroid hormone receptor interactor 12 |
| TTC21B | 2.1786764 | Tetratricopeptide repeat domain 21B |
| TUBA1C | -3.2958088 | Tubulin alpha 1c |
| TUBA3C | -2.4673393 | Tubulin alpha 3c |
| TUBB3 | -8.211237 | Tubulin beta 3 class III |
| TUBB4B | -2.5735104 | Tubulin beta 4B class IVb |
| UBE2F | -2.2094207 | Ubiquitin conjugating enzyme E2 F (putative) |
| UIMC1 | -2.096621 | Ubiquitin interaction motif containing 1 |
| WWC3 | -1.7466848 | WWC family member 3 |
| XRCC5 | -2.593 | X-ray repair cross complementing 5 |
Fig 3qRT-PCR analysis of disease-associated alterations in gene expression within the Cb-NHL signature.
PBMC samples from patients with acute Q fever, persistent C. burnetii infection, C. burnetii associated NHL, C. burnetii lymphadenitis and NHL-controls were compared to healthy controls by using qRT-PCR. The expression of genes from the Cb-NHL signature were evaluated as fold change of investigated gene/ β-actin mRNA. (A) Principal component analysis reveals the overlap between the modulated genes (log2 fold change) of the three groups of patients with persistent C. burnetii infection (blue), C. burnetii associated NHL (purple) or C. burnetii lymphadenitis (green) and NHL-control (red). (B) Modulated genes from Cb-NHL (log2 fold change) were represented as a heatmap with samples in columns and genes in rows. Gene expression was colored from blue (down-regulated) to red (up-regulated). (C) Comparison of patients affected by persistent C. burnetii infection to patients with lymphoma and lymphadenitis led to the identification of MIR17HG, REL and SP100 as significantly up-regulated in patients with lymphoma and lymphadenitis. (D) In patients with lymphadenitis, BCL2 and ETS1 were significantly up-regulated.
Quantitative-RT-PCR analysis.
| Gene expression profile | Gene symbol | Fold change (mean) | Group of patients | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| NHL-control | Persistent | |||||||||
| NHL-control | Persistent | |||||||||
| MIR17HG | 2.089 | 5.058 | 302.3 | 567.0 | <0.0001 | Up | Up | Up | Up | |
| REL | 6.304 | 1.593 | 118.5 | 63.60 | 0.0001 | Up | Up | Up | Up | |
| BAG1 | 2.709 | 1.414 | 3.277 | 5.161 | 0.0008 | Up | - | Up | Up | |
| OGG1 | 1.629 | 0.7404 | 3.418 | 6.006 | 0.0012 | Up | Down | Up | Up | |
| SP100 | 0.1206 | 1.455 | 1134 | 306.6 | <0.0001 | Down | - | Up | Up | |
| NCOA1-v1 | 0.311 | 1.140 | 2.835 | 2.591 | <0.0001 | Down | - | Up | Up | |
| CREBBP | 0.7572 | 2.494 | 0.5745 | 0.7397 | 0.0001 | Down | Up | Down | Down | |
| ETS1 | 2.683 | 0.8918 | 3.457 | 2.477 | 0.0034 | Up | Down | Up | Up | |
| BCL2 | 5.885 | 1.650 | 4.961 | 3.038 | 0.0044 | Up | Up | Up | Up | |
| CASP4 | 1.317 | 1.078 | 1.798 | 2.952 | 0.0001 | - | - | Up | Up | |
| CASP8 | 2.916 | 1.237 | 641.4 | 328.3 | 0.0018 | Up | - | Up | Up | |
| CASP2 | 1.732 | 2.032 | 127.8 | 130.1 | 0.0084 | Up | Up | Up | Up | |
| TLR7 | 2.214 | 2.460 | 408.4 | 2179 | <0.0001 | Up | Up | Up | Up | |
| JAK3 | 9.395 | 0.4601 | 12.46 | 29.80 | 0.0001 | Up | Down | Up | Up | |
P value is calculated as a fold change in comparison to the control group (healthy donors)
Up = fold change>1.5; down = fold change<1; -: fold change between 1 and 1.5
Fig 4(A) Link between genes contained in Cb-NHL signature and infection by cancer-associated microorganisms. Venn diagram showing overlap between genes contained in the Cb-NHL signature that are also deregulated in non-Hodgkin lymphoma associated with Epstein-Barr virus (EBV), human T lymphocyte virus (HTLV), Campylobacter jejuni, Helicobacter pylori, Borrelia burgdorferi or Chlamydia psittaci. (B) Pathophysiological mechanism. Fom persistent C. burnetii infection (endocarditis, vascular infection), to C. burnetii lymphadenitis and lymphoma. Peripheral blood monocyte cells genomic transcriptional profiles indicated an overexpression of BCL2 and ETS1 mRNAs in cases of C. burnetii lymphadenitis and an overexpression of MIR17HG, REL and SP100 genes in cases of C. burnetii associated lymphoma. All these gene are related to the inhibition of apoptosis and/or cellular proliferation.